Takeda in Cambridge has joined forces with UCL for one of the largest university partnerships the Japanese company has ever formed in the UK.
The new research collaboration aims to identify and validate novel target genes for the treatment of neurodegenerative disease.
Key targets include motor neurone disease (MND or ALS), Huntington’s disease and Parkinson’s disease.
The collaboration, which includes support from the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre, will initially run for three years. It will be carried out by Takeda Cambridge Limited, Takeda’s research unit based in the Science & Technology cluster.
Dr Tetsuyuki Maruyama, general manager of Takeda’s Pharmaceutical Research Division said: “At Takeda, we work with partners to accelerate innovation. We are looking forward to collaborating with UCL’s world-class researchers.
“This co-operation will help us to identify and validate novel therapeutic pathways in central nervous system diseases, which is one of Takeda’s core therapeutic areas – ultimately leading to new treatments for patients suffering from neurodegenerative disorders.”
Professor Alan Thompson, Dean of the Faculty of Brain Sciences, UCL underlined the significant nature of the research collaboration. He said: “Developing new treatments for devastating neurodegenerative diseases is an absolutely essential but very challenging goal and requires the complementary expertise of academia and industry, if it is to be achieved.
“This UCL-Takeda collaboration represents just such a partnership and as Dean of the Faculty of Brain Sciences, I am delighted to see it evolving so well.”
UCL is a world leading university in CNS research with a world class reputation in the field of neurodegeneration and rare neurological disorders. Its Institute of Neurology is a centre of significant investment for dementia research with a highly engaged and interactive faculty.
Takeda Cambridge is a subsidiary of Takeda Pharmaceutical Company Limited, a research-based global pharmaceutical company.
As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine.
Takeda Cambridge is Takeda’s research unit in the UK focused on target identification and drug discovery, with CNS being one of its key focus areas.
Source: Business Weekly